Mitogen-activated protein kinase kinase kinase 7 (MAP3K7)

Mitogen‑activated protein kinase kinase kinase 7 (MAP3K7), also known as TAK1, is a serine/threonine protein kinase that acts upstream within the mitogen‑activated protein kinases cascade. It mediates signal transduction induced by various stimuli including TGF-beta, BMPs, TNF-alpha, IL‑1β, Toll-like receptors activation, CD40 ligation on B cells—and integrates these signals primarily through formation of complexes with TAB proteins (TAB1/TAB2/TAB3). Upon activation by pro-inflammatory cytokines or cellular stressors it phosphorylates downstream kinases leading to activation of transcription factors such as NF-kappaB and AP‑1. These events regulate diverse biological processes including apoptosis/survival decisions; immune responses; inflammation; cell proliferation; differentiation; and adaptation to environmental stresses. Overexpression or hyperactivation has been linked to oncogenesis—especially liver cancers—and inflammatory pathologies while loss-of-function disrupts normal tissue homeostasis.

Other names

TAK1TGF-beta activated kinase 1MEKK7Transforming growth factor beta-activated kinase 1

Drugs or inhibitors targeting this molecule typically act by inhibiting its serine/threonine protein kinase activity. This leads to suppression of downstream signaling pathways such as NF-kappaB and AP‑1 activation, which are involved in inflammation and tumorigenesis. Inhibition can sensitize cancer cells to chemotherapeutic agents by blocking pro-survival signals mediated through these pathways.